Drug Eluting Stent Market Size Reaches $8.94 Billion In 2026: What Is Driving Growth?
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Drug Eluting Stent Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The drug eluting stent market size has experienced robust expansion in recent years. It is anticipated to increase from $8.26 billion in 2025 to $8.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The historical development can be ascribed to an escalating prevalence of coronary artery disease, an uptick in percutaneous coronary intervention procedures, a growing occurrence of lifestyle-related cardiovascular conditions, the broadening of cardiac catheterization labs, and enhanced clinical outcomes when compared to bare-metal stents.
The drug eluting stent market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $11.7 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth during the forecast period is attributable to factors such as an expanding aging population, a heightened demand for minimally invasive cardiac procedures, increasing awareness regarding advanced stent technologies, the proliferation of specialty cardiac clinics, and increased healthcare spending on cardiovascular care. Significant trends expected during this period involve the increasing adoption of biodegradable polymer stents, a growing inclination towards polymer-free drug-eluting stents, their expanded application in complex coronary interventions, a movement towards long-term restenosis prevention, and a heightened demand for enhanced drug release control.
Get A Free Sample Report With In-Depth Market Insights:
Drug Eluting Stent Market Demand Drivers Opening New Revenue Streams
The increasing prevalence of coronary heart disease (CHD) is anticipated to drive expansion in the drug-eluting stent market moving ahead. CHD refers to a condition characterized by the constriction or obstruction of coronary arteries from plaque accumulation, which can result in serious issues like heart attacks or angina. Factors contributing to the rise in coronary heart disease include inactive lifestyles, inadequate nutrition, an aging global demographic, and improved diagnostic awareness. Drug-eluting stents (DES) offer advantages in treating coronary heart disease by efficiently unblocking constricted arteries and delivering drugs to inhibit the re-narrowing, known as restenosis, of these vessels. As an illustration, data from August 2025, provided by the National Center for Biotechnology Information, a US governmental body, indicates that from 2025 to 2050, cardiovascular disease is forecasted to experience a substantial surge, with its prevalence climbing by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%. This trajectory suggests approximately 35.6 million cardiovascular deaths by 2050, an increase from 20.5 million in 2025. This growing incidence of coronary heart disease is anticipated to fuel the expansion of the drug-eluting stent market.
Drug Eluting Stent Market Segment Performance And Emerging Opportunities
The drug eluting stent market covered in this report is segmented –
1) By Product: Polymer-Based, Polymer-Free
2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
4) By Application: Coronary Diseases, Peripheral Vascular Diseases
5) By End-User: Hospitals, Specialty Clinics
Subsegments:
1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents
2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents
Drug Eluting Stent Market Trends Powering Strategic Industry Growth
Leading companies within the drug eluting stent market are concentrating on developing innovative products, such as low-profile, high-flexibility stents, to enhance deliverability in complex coronary anatomies and improve patient outcomes. These specific stents are drug eluting stents engineered with a reduced crossing profile and increased flexibility, allowing for easier navigation through narrow, tortuous, or calcified coronary arteries, while maintaining effective drug delivery to prevent restenosis. For example, in May 2024, Abbott Laboratories, a U.S.-based global healthcare company, launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. The XIENCE Sierra features a novel stent design offering best-in-class deliverability, with significantly reduced crossing force when compared to competitors. It also incorporates a thinner balloon and an optimized MULTI LINK structure that enhances flexibility, while its high longitudinal strength ensures scaffold stability and resistance to deformation. Additionally, it provides a wide expansion range, permitting precise treatment even when vessel diameters vary markedly along the lesion, enabling interventional cardiologists to treat complex, calcified, or difficult-to-reach lesions with improved precision and safety.
Drug Eluting Stent Market Competitive Overview And Top Companies
Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation
View The Full Drug Eluting Stent Market Report:
Drug Eluting Stent Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
